The Short Answer
Can foreign companies manufacture pharmaceuticals in the Dominican Republic?
Yes. Foreign companies can manufacture pharmaceuticals and medical products in Dominican Republic free zones under Law 8-90, with 100% exemption from income tax, import duties, and export taxes. The sector benefits from CAFTA-DR duty-free access to the U.S. market and 2–4 day shipping to the U.S. East Coast via Port Caucedo. Facilities operate under CNZFE regulation and can pursue FDA-aligned and ISO-certified production. Medical and pharmaceutical products are among the Dominican Republic’s largest free-zone export categories.
Related: Law 8-90 Tax Exemptions · DR Free Zones Guide · DR vs Mexico · Get a free analysis
QUICK ANSWER
Pharmaceutical manufacturers in Dominican Republic free zones benefit from full income tax exemption under Law 8-90, CAFTA-DR duty-free U.S. access, and a regulatory environment that supports FDA foreign establishment registration — at manufacturing costs significantly below U.S. domestic equivalents.
The DR Pharmaceutical Sector
The Dominican Republic has a growing pharmaceutical manufacturing sector, with both domestic production for the DR market and export-oriented operations in free zones. Free zone pharmaceutical manufacturers export primarily to the United States, Caribbean, and Latin American markets. The sector has attracted attention from Israeli pharmaceutical companies exploring Caribbean Corridor operations as part of U.S. market entry strategies.
FDA Registration for DR-Based Pharmaceutical Manufacturers
Pharmaceutical manufacturers in the Dominican Republic exporting to the United States must register with FDA as foreign drug establishments under 21 CFR Part 207. The DR facility is subject to FDA inspection and must comply with Current Good Manufacturing Practice (cGMP) requirements. Unlike Puerto Rico (U.S. territory), DR pharmaceutical facilities are subject to the full foreign establishment registration and inspection framework — a significant consideration for complex drug manufacturers where FDA compliance adds operational overhead.
CAFTA-DR Eligibility for Pharmaceutical Products
Pharmaceutical products classified under HTS Chapter 30 can qualify for CAFTA-DR duty-free U.S. entry if they satisfy the applicable rules of origin. Most pharmaceutical formulation and finishing operations — mixing, tableting, encapsulating, and packaging active pharmaceutical ingredients into finished dosage forms — meet the tariff shift requirement. Rules of origin analysis is required for each specific product and HTS code.
What Sectors Work Best
Generic pharmaceutical manufacturing for U.S. distribution, nutraceuticals and dietary supplements, veterinary pharmaceuticals, and medical consumables represent the highest-activity categories for DR free zone pharmaceutical operations. For complex biologics or new molecular entity manufacturing requiring intensive FDA oversight, Puerto Rico’s U.S. territory regulatory equivalence may be a better fit. Contact EGS to assess your pharmaceutical manufacturing mandate.
Continue Your Research
Complete Guide: Manufacturing in the Dominican Republic – Everything foreign manufacturers need to know about production in DR free zones.
How to Set Up Your DR Free Zone Company – Step-by-step company formation, licensing, and compliance.
RELATED: SECTOR RESOURCES
How DR free zone manufacturing enables duty-free U.S. market entry.
CAFTA-DR Manufacturing GuideSector-specific rules of origin and duty-free eligibility.
DR Free Zone Tax IncentivesLaw 8-90 full exemption structure for qualifying manufacturers.
Apply to EGSAssess your corridor mandate with EGS.